MedTrace Logo

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

NCT04195997 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-12-12

No results posted yet for this study

Summary

The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in patients with non-valvular atrial fibrillation undergoing percutaneous left atrial appendage occlusion.

Conditions

  • Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk

Interventions

DRUG

Bivalirudin

Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.

DRUG

Heparin

heparin during left atrial appendage occlusion.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • XIAOCHUN ZHANG, MD · Department of Cardiology, Zhongshan Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-12-30
Completion
2021-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04195997 on ClinicalTrials.gov